| Target Price | $15.10 |
| Price | $1.25 |
| Potential |
1,112.53%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Sonoma Pharmaceuticals, Inc. 2027 .
The average Sonoma Pharmaceuticals, Inc. target price is $15.10.
This is
1,112.53%
register free of charge
$15.54
1,148.19%
register free of charge
$14.95
1,100.64%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Sonoma Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sonoma Pharmaceuticals, Inc. stock has an average upside potential 2027 of
1,112.53%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Million $ | 19.53 | 21.90 |
| 36.67% | 12.11% | |
| Net Margin | -16.28% | -10.11% |
| 32.75% | 37.91% |
3 Analysts have issued a sales forecast Sonoma Pharmaceuticals, Inc. 2027 . The average Sonoma Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Sonoma Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2027. The average Sonoma Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.89 | -0.46 |
| 32.26% | 75.66% | |
| P/E | negative | |
| EV/Sales | 0.03 |
3 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast for earnings per share. The average Sonoma Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sonoma Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


